n,n-dibenzyldaunorubicin has been researched along with dactinomycin in 1 studies
| Studies (n,n-dibenzyldaunorubicin) | Trials (n,n-dibenzyldaunorubicin) | Recent Studies (post-2010) (n,n-dibenzyldaunorubicin) | Studies (dactinomycin) | Trials (dactinomycin) | Recent Studies (post-2010) (dactinomycin) |
|---|---|---|---|---|---|
| 5 | 0 | 0 | 19,045 | 355 | 969 |
| Protein | Taxonomy | n,n-dibenzyldaunorubicin (IC50) | dactinomycin (IC50) |
|---|---|---|---|
| RAD51 | Homo sapiens (human) | 32.1 | |
| Growth factor receptor-bound protein 2 | Homo sapiens (human) | 5 | |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | 9 | |
| Growth factor receptor-bound protein 2 | Mus musculus (house mouse) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganapathi, R; Grabowski, D; Israel, M; Schmidt, H; Seshadri, R | 1 |
1 other study(ies) available for n,n-dibenzyldaunorubicin and dactinomycin
| Article | Year |
|---|---|
Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Topics: Aminoacridines; Amsacrine; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line; Dactinomycin; Daunorubicin; DNA; Doxorubicin; Drug Interactions; Drug Resistance; Leukemia P388; Leukemia, Experimental; Menogaril; Mice; Mitoxantrone; Naphthacenes; Nogalamycin; Trifluoperazine | 1985 |